Group 1 - The core viewpoint of the news is that Kangnuo Biopharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Guotou Securities International as its sole sponsor [1] - Kangnuo Biopharmaceutical focuses on mitochondrial medicine and health products, covering research and development, drug production, and commercialization [1] - The company is primarily researching diseases caused by mitochondrial dysfunction and aims to apply NAD+ in the fields of cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging [1] Group 2 - The company is registered in the People's Republic of China and operates as a joint-stock company [2] - The listing will involve H shares, with the number of shares depending on the exercise of options [3] - The maximum price for each H share is set in Hong Kong dollars, with additional fees including a brokerage commission and various transaction fees [3]

智通财经APP获悉，据港交所1月25日披露，康诺生物制药股份有限公司 - B(简称：康诺生物)向港交所 主板递交上市申请，国投证券国际为其独家保荐人。招股书显示，康诺生物是一家专注于线粒体医学与 健康产品的生物制药企业，业务涵盖研发、药物生产及商业化。公司重点研究因线粒体功能障碍引起的 疾病，致力于将NAD+应用于心血管疾病、神经退行性疾病、生殖健康及衰老等领域的科学研究.. 图投證券國際 [編纂]、[編纂]及[編纂] (於中華人民共和國註冊成立的股份有限公司) l 細景| [编纂]項下的[编纂]數目 : [编纂]股H股(視乎]编纂]行使與否而定) 股份代號 : [ ·] 獨家保薦人及[編纂] Knature Biopharmaceutical Co., Ltd. 康 諾生物製藥股份有限公司 國投證券國際 [編纂]數目 : [編纂]股H股(可予[編纂]) [编纂]數目 : [编纂]股H股(可予[编纂]及視乎[编纂]行使 與否而定) 最高[編纂] : 每股H股[編纂]港元,另加1.0%經紀佣金、 0.0027%證監會交易徵費、0.00565%聯 交所交易費及0.00015%會財局交易徵費 (須於申請時以港元繳足 ...